Informação sobre produto
- CT-3, CPL-7075, HU-239, IP-751, DMH-THC-11-OIC
- (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid
- 6H-Dibenzo[b,d]pyran-9-carboxylic acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-
- 6H-Dibenzo[b,d]pyran-9-carboxylic acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR-trans)-
- CT 3
Ajulemic acid is a cannabinoid CB2 agonist potentially for treatment of skin-predominant dermatomyositis. Ajulemic acid shows useful analgesic and anti-inflammatory effects without causing a subjective high. It is being developed for the treatment of neuropathic pain and inflammatory conditions such as arthritis. It does not however share the anti-emetic effects of other cannabinoids but may be useful for treating pain and chronic inflammatory conditions where nausea is not present.